Dr. Suryanarayan is a Clinical Assistant Professor with the Division of Hematology who has been with the DoM since September 2015. She obtained a Master’s degree in Health Research Methodology from McMaster University and has completed the Clinical Investigator Program in thrombosis. She currently devotes 20% of her time to research in the area of thrombosis. She is specifically interested in expanding the clinical applications of direct oral anticoagulants (DOACs), which target specific components of the clotting cascade and provide alternatives to the more traditional anti-coagulants, warfarin and low molecular weight heparin (LMWH).
She was recently awarded a CanVECTOR Pilot Trial award to conduct a Canadian multi-site feasibility study of apixaban (a DOAC that directly inhibits factor Xa) versus LMWH for the treatment of catheter related thrombosis in cancer patients. If successful, it is hoped that this pilot trial will lead to a full-scale multi-site randomized controlled trial. Through this work, the way is being paved for Calgary to join national leaders in thrombosis-related clinical trials.
Dr. Suryanarayan also holds funding from the department of Hematology for a prospective cohort study examining the impact of multifaceted intervention in optimizing and reducing inappropriate DOAC use in a tertiary care centre.
Check out the following publications by Dr. Suryanarayan:
- Suryanarayan D, Schulman S. When the rubber meets the road: adherence and persistence with non-vitamin K antagonist oral anticoagulants and old oral anticoagulants in the real world – a problem or a myth? Semin Thromb Hemost. 2014 Nov;40(8):852-9. doi: 10.1055/s-0034-1395156
- Suryanarayan D, Schulman S. Potential antidotes for reversal of old and new oral anticoagulants. Thromb Res. 2014 May;133 Suppl 2:S158-66. doi: 10.1016/S0049-3848(14)50026-6
- Suryanarayan D, Garcia D. Ask the Hematologists: Anti-Phospholipid Antibodies and Pregnancy. The Hematologist: ASH News and Reports. 2014; 11(3):4-5.